The Key Laboratory of Tissue Engineering, Shanghai 9th People's Hospital, Shanghai JiaoTong Universtiy School of Medicine, Shanghai, China.
Tissue Eng Part A. 2010 Mar;16(3):971-82. doi: 10.1089/ten.TEA.2009.0516.
The osteogenic differentiation potential of umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) has been documented previously, and partially demineralized bone matrix (pDBM) represents a promising candidate for bone tissue engineering scaffolds. In this study, pDBM scaffolds derived from porcine cancellous bone were evaluated for their ability to support human UCB-MSCs osteogenic differentiation in vitro and bone-forming capacity in vivo to assess the potential use of UCB-MSCs in bone tissue engineering applications. MSCs were isolated from full-term human UCB and expanded, and their cell surface antigen markers and multilineage capability to differentiate into osteoblasts, chondrocytes, and adipocytes were analyzed. The in vitro proliferation and osteogenic differentiation of UCB-MSCs loaded onto the three-dimensional pDBM scaffolds were determined. Critical-sized full-thickness circular defects (5 mm in diameter) created bilaterally in the parietal bones of athymic rats were treated with one of the following: osteogenically induced UCB-MSC/pDBM composites (Group A, n = 8), noninduced UCB-MSC/pDBM composites (Group B, n = 8), pDBM alone (Group C, n = 8), or left untreated (Group D, n = 8). Microcomputed tomography analysis showed that new bone was formed in Group A at 6 weeks postimplantation, and greater bone volume and density were found after 12 weeks. In other groups, new bone formation was not evident after 6 weeks, and no bone union was found at 12 weeks. Histological examination revealed that the defect was repaired by tissue-engineered bone in Group A at 12 weeks, and fibrous union was observed in Groups B, C, and D. These results demonstrate that pDBM can support osteogenic differentiation of human UCB-MSCs in vitro and in vivo, and UCB-MSCs may serve as an alternative cell source for bone tissue engineering and regeneration.
先前已有研究证明脐带血来源的间充质干细胞（UCB-MSCs）具有成骨分化潜能，部分脱矿骨基质（pDBM）是一种很有前途的骨组织工程支架候选材料。本研究评估了源自猪松质骨的 pDBM 支架在体外支持人 UCB-MSCs 成骨分化和体内成骨能力，以评估 UCB-MSCs 在骨组织工程应用中的潜力。从足月人 UCB 中分离并扩增 MSC，分析其细胞表面抗原标志物和向成骨细胞、软骨细胞和脂肪细胞分化的多能性。测定负载在三维 pDBM 支架上的 UCB-MSCs 的体外增殖和成骨分化。在无胸腺大鼠双侧顶骨上创建 5mm 直径的全层圆形临界尺寸缺损，用以下方法之一进行治疗：成骨诱导的 UCB-MSC/pDBM 复合物（A 组，n = 8）、非诱导的 UCB-MSC/pDBM 复合物（B 组，n = 8）、pDBM 单独（C 组，n = 8）或未治疗（D 组，n = 8）。微计算机断层扫描分析显示，植入后 6 周 A 组形成新骨，12 周后发现骨体积和密度更大。在其他组中，6 周后未见新骨形成，12 周时未见骨融合。组织学检查显示，A 组在 12 周时通过组织工程骨修复了缺损，B、C 和 D 组观察到纤维性愈合。这些结果表明，pDBM 可支持人 UCB-MSCs 的体外和体内成骨分化，UCB-MSCs 可能是骨组织工程和再生的替代细胞来源。
